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Abstract
Tissue factor (TF) is the primary initiator of the coagulation cascade and plays an essential role in
hemostasis. TF also contributes to many diseases, including cancer. The correlation between
thrombosis and cancer has been recognized for more than a century. However, it is only in the past
two decades that we have begun to understand the role of TF in tumor biology. TF expression is
upregulated on both tumor and host cells in cancer patients as well as in the circulation. Clinical
observations indicate a direct correlation between the levels of tumor cell TF expression and poor
prognosis for cancer patients. The role of TF in tumor biology has been extensively studied using
various mouse tumor models. It has been demonstrated that tumor cell TF contributes to tumor
metastasis, growth, and angiogenesis. The role of host TF in tumor progression is less clear. Recently
developed mouse models with altered levels of TF may be useful in further analysis of the role of
host cell TF in cancer.
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Tissue factor (TF) is a 47-kDa transmembrane receptor that binds plasma factor VII/VIIa (FVII/
FVIIa).1 This TF:FVIIa bimolecular complex initiates blood coagulation by activating both
factor X (FX) and factor IX (FIX), which leads to the generation of thrombin, fibrin deposition,
and platelet activation.1 TF expression by perivascular cells provides a hemostatic barrier to
limit hemorrhage after vessel injury.2 In addition to its essential role in hemostasis, TF activates
cell signaling.3 The formation of the TF:FVIIa and TF:FVIIa:FXa complexes leads to cleavage
of protease-activated receptors (PARs) at the cell surface. Specifically, TF:FVIIa activates
PAR-2, whereas TF:FVIIa:FXa can activate both PAR-1 and PAR-2,3 which both lead to the
recruitment of G proteins and the activation of various intracellular signaling pathways. For
example, it has been shown that the TF:FVIIa–PAR-2 pathway induces expression of the
proangiogenic cytokine IL-8 in tumor cells4 and also contributes to retinal neoangiogenesis.5
In addition, the TF cytoplasmic domain can regulate the p38 mitogen-activated kinase and
extracellular signal-regulated kinase1/2 and the rac pathways,6 as well as suppress integrin-
mediated migration of cells.7
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Increased intravascular TF expression is observed in a variety of diseases including cancers.
2,8 TF is expressed by the tumor cells themselves and is induced in host cells, such as
monocytes, macrophages, and endothelial cells.8 This may contribute to the prothrombotic
state that is associated with cancer.9 TF is overexpressed in many types of human cancers, and
clinical studies have shown a correlation between the levels of TF expression and poor
prognosis.10–13 Several studies using different mouse tumor models demonstrated that TF
plays a key role in tumor biology. In this review, we will summarize the current knowledge
regarding the role of TF in tumor growth, angiogenesis, and metastasis, focusing on the data
obtained from mouse models. In addition, we will discuss the generation of new mouse lines,
with modified TF expression, and how these mice could be used to further elucidate the role
of TF in tumor biology.
MOUSE TUMOR MODELS
Subcutaneous xenograft mouse models have been used for almost 40 years.14,15 Because this
model is relatively easy to establish, it has become very popular for use to study the role of
different proteins in tumor biology. Human tumor cells cultured in vitro are injected into
subcutaneous tissue of immunodeficient mice, which prevents the rejection of foreign cells.
Severe combined immunodeficient (SCID) mice lack the ability to make T and B lymphocytes,
whereas mutation in nude mice results in the reduction in the number of T cells.16,17 However,
there are several limitations with the xenograft model. These include the artificial nature of
tumor cell lines passaged in culture for many generations, species differences between tumor
and stromal cells, the subcutaneous location of the xenograft, and the lack of an adaptive
immune response in the host. Some of these concerns can be overcome by using
immunocompetent allograft models. However, given the heterogenous nature of cancers, the
relevance of studying mouse tumors can be questioned. For some types of cancers,
subcutaneous injection of tumor cells can be replaced with more relevant orthotopic injection,
such as injection of breast cancer cells into the mammary pad of the mice. More recently,
genetically engineered mouse (GEM) tumor models have been developed. In these models,
tumor development is driven by expression of oncogenes or loss of tumor suppressors. The
first generation of these GEM models used transgenic and standard gene targeting (knock-in
or knockout) technology. More recently, conditional strategies have been used to generate mice
with controlled gene expression in both a tissue- and a time-dependent manner. Although GEM
models have their own limitations, their main advantage is the ability to drive tumor
development with defined genetic changes in syngeneic tumor-host compartments. More
detailed information about the pros and cons of different mouse cancer models can be found
in recent reviews focusing on this subject.18–20
ROLE OF TF IN TUMOR GROWTH AND TUMOR ANGIOGENESIS
During the past 15 years, several studies have provided evidence that supports the importance
of TF in tumor growth. Zhang and colleagues were the first to show a contribution of TF to
tumor growth and angiogenesis in mice. Mouse fibrosarcoma cells overexpressing TF
developed larger tumors compared with control cells.21 Tumor size correlated with the amount
of vascular endothelial cell growth factor (VEGF) secreted by the cells and the vascular density
within tumors, suggesting that TF expression contributes to tumor growth by promoting
angiogenesis.21 Similar results have been observed in studies using human pancreatic
adenocarcinoma, melanoma, and colorectal carcinoma cell lines.22–24 One study indicated that
the TF cytoplasmic domain regulates VEGF production and angiogenesis.22 Blocking
TF:FVIIa activity with either tissue factor pathway inhibitor (TFPI) or nematode anticoagulant
protein NAPc2 inhibited the growth of mouse Lewis lung carcinoma in mice, whereas NAP5,
a specific inhibitor of FXa, did not show any antitumor effects.25 Based on these results, it has
been proposed that the TF:FVIIa complex contributes to tumor growth by activating PAR-2,
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independent of downstream coagulation proteases FXa and thrombin.25 However, a possible
contribution of TF to tumor growth via FXa and thrombin generation has been demonstrated
by Anderson and colleagues. In their experiments, a humanized anti-TF antibody CNTO 859,
which acts primarily as a competitive inhibitor of FX binding to the TF:FVIIa complex
preventing the generation of FXa, dramatically reduced tumor growth in an orthotopic breast
cancer model.26 Recently, it has been demonstrated that TF-dependent signaling contributes
to tumor growth. An antibody (10H100) that selectively blocks TF:FVIIa signaling
significantly reduced tumor growth.27 In addition, an inhibitory anti–PAR-2 but not an
inhibitory anti–PAR-1 antibody reduced tumor growth.27 These results suggest that selective
blockade of TF:FVIIa–PAR-2 signaling without interfering with TF:FVIIa procoagulant
function may provide a novel strategy to reduce tumor growth in cancer patients without
impairing hemostasis.
In contrast, there are some studies indicating that TF is not required for tumor growth. First,
mouse teratomas and teratocarcinomas derived from TF+/+, TF+/−, and TF−/− embryos
generated similar-sized tumors in immunodeficient SCID mice.28 Another publication
demonstrated that increasing TF expression in human melanoma cells did not increase VEGF
expression or promote growth and vascularization of tumors.29 Most recently, it was shown
that expression of either wild-type TF or a truncated form of TF lacking the cytoplasmic domain
in TF−/− fibroblastoma cells did not affect tumor growth.30 Taking together, these studies
indicate that TF plays an important role in tumor growth and tumor-related angiogenesis in
many but not all tumors, which probably reflects the heterogeneity of tumor cells.
ROLE OF TF IN TUMOR METASTASIS
Tumor metastasis is a multistep process that consists of intravasation of tumor cells from the
primary tumor into the circulation, survival in the circulation, arrest and extravasation from
the microcirculation, and finally tumor growth at a distal site. SCID or nude mice injected
intravenously with human tumor cells are widely used as experimental metastasis models.
Metastatic cells have been found to express higher levels of TF compared with nonmetastatic
cells, suggesting that TF may play a direct role in tumor cell metastasis.31 Mueller and
colleagues showed that inhibition of TF on two human melanoma cell lines significantly
reduced lung metastasis in SCID mice.31 Because the antibody used to block TF (5G9)
specifically recognized only human TF, it could be concluded that tumor cell–derived TF is
sufficient to support metastasis. A subsequent study showed that downregulation of TF
expression by delivery of a small interfering RNA in human melanoma LOX-L cells reduced
pulmonary metastasis in nude mice.32 Most recently, Ngo and colleagues demonstrated that a
humanized anti-TF monoclonal antibody (CNTO 859) efficiently inhibited experimental lung
metastasis of human breast carcinoma cells in SCID mice.26 Both proteolytic activity of the
TF:FVIIa complex and the phosphorylation of TF cytoplasmic domain is required for full
metastatic properties of the tumor cells in SCID mice.33 The importance of TF cytoplasmic
domain in metastasis was independently confirmed by Bromberg and colleagues.29
Tumor metastasis also has been studied using immunocompetent mice injected with mouse
tumor cells. Consistent with the data obtained from the mouse xenograft model using
immunodeficient mice, blocking TF activity on mouse melanoma cells B16F10 with anti-
mouse TF antibody or reducing TF expression in these cells using a small interfering RNA
significantly reduced lung metatstasis.34,35 In addition, TFPI also significantly reduced
experimental lung metastasis of B16F10 cells.36 Furthermore, C57Bl/6-derived fibrosarcoma
cells that were genetically incapable of TF expression showed no metastatic potential compared
with the high metastatic abilities of fibrosarcoma cells expressing TF.30
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Data obtained from both immunodeficient and immunocompetent mouse models strongly
suggest that tumor cell TF contributes to tumor dissemination via a mechanism involving
thrombin generation. T his conclusion is supported by multiple observations demonstrating
that thrombin-mediated proteolysis, as well as fibrinogen- and PAR-mediated platelet
activation, play roles in tumor metastasis.30,37–39 However, the importance of the TF
cytoplasmic domain in metastasis depends on the models. In contrast with the contribution of
the cytoplasmic domain of TF to metastasis in xenograft models using immunodeficient mice,
a recent publication by Palumbo and colleagues showed that TF expressed by mouse-derived
fibrosarcoma cells supports metastasis through mechanisms independent of the cytoplasmic
domain of TF but dependent on circulating hemostatic factors and platelet activation.30 The
authors proposed that multiple experimental differences between their and previous
experiments may explain the discrepancy.
ROLE OF TUMOR-DERIVED VERSUS HOST-DERIVED TF IN TUMOR
PROGRESSION
In contrast WITH the abundant literature focusing on the role of tumor cell–derived TF, the
role of TF expressed by host cells in tumor progression has not been explored extensively. This
is probably due to the fact that the absence of TF leads to intrauterine lethality40 and that until
recently there were no inhibitory anti-mouse TF antibodies.34 It has been proposed that TF
expressed on the tumor cells or endothelial cells, in patients with invasive breast cancer, can
regulate tumor angiogenesis.41 One study demonstrated that blocking the host TF with anti-
mouse TF antibody had no effect on the growth of human mammary carcinomas in
immunodeficient mice.42 However, in the same model, combined therapy of anti-mouse and
anti-human TF antibodies inhibited tumor growth more efficiently than by using only an anti-
human TF antibody treatment.42 These results would suggest that the host TF plays some role
in tumor growth.
In the past few years, our laboratory has generated several mouse models with altered TF
expression. Those models include low TF mice that express very low levels of human TF (1%
of wild-type TF levels) in the absence of mouse TF.43 In collaboration with Janusz Rak, we
used low TF mice to study the role of host TF in tumor growth. Mouse tumor cell lines were
highly tumorigenic in both wild-type and low-TF mice. However, injection of TF-deficient
cells into low-TF mice resulted in almost complete inhibition of tumor growth.8
A second line of mice that we have generated contained a TF gene flanked by loxP site—so-
called TF floxed mice.44 These mice can be bred with mice expressing the Cre recombinase
in different cell types to determine the role of TF derived from different host cells in tumor
biology. We further investigated the role of host TF expressed by different cell types in tumor
growth and metastasis using TF floxed/LysMCre (specific deletion of TF in mature neutrophils
and monocytes/macrophages) and TF floxed/Tie-2Cre mice (endothelial cell and
hematopoietic cell specific deletion). The reduction of TF expression in macrophages isolated
from both TF floxed/LysMCre and TF floxed/Tie-2Cre mice was ~95% (Pawlinski and
Mackman, unpublished data). Our preliminary results indicate that neither LysMCre-driven
nor Tie-2Cre-driven deletion of TF had an effect on tumor growth caused by subcutaneous
injection of mouse Lewis lung carcinoma cells (Zhang, Pawlinski, Mackman, and Liu,
unpublished data). We also did not see significant differences between these two mouse strains
and littermate controls in a lung metastasis model using mouse Lewis lung carcinoma cells
(Zhang, Pawlinski, Mackman, and Liu, unpublished data). More detailed studies, involving
different mouse tumor cell lines, are necessary to fully elucidate the role of host TF in tumor
biology.
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In addition to investigating the role of host TF in tumor biology using allograft approach, TF
floxed mice expressing appropriate Cre recombinase can be crossed with various GEM mouse
tumor models allowing in vivo manipulation of TF expression in specific tumor or stroma cells.
Alternatively, a similar breeding strategy can be used to generate primary mouse tumor cell
lines containing the TF floxed allele. After in vitro transfection with a vector expressing the
Cre recombinase, tumor cell lines lacking TF can be established and used in allograft tumor
models. Both mouse models with altered levels of TF, as well as recently developed mouse
strains expressing normal levels of human TF,44,45 may be very useful to further explore the
role of host versus tumor cell TF in tumor biology. In addition, these new mouse models can
be used to study the role of TF in cancer-associated thrombosis.
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